Compare Iron Mountain Inc (IRM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs TG Therapeutics Inc — how do they compare? Iron Mountain Inc trades at $114.51 (market cap $34.46B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Iron Mountain Inc is far larger — about 4.2× TG Therapeutics Inc's market cap, and Iron Mountain Inc pays a 2.99% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and TG Therapeutics Inc for 16 Days on average.
| IRM | TGTX | |
|---|---|---|
Market Cap | $34.46B | $8.16B |
Volume | 1,379,608 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $59.06 |
52-Week Low | $78.86 | $26.94 |
Typical Hold Time | 80 Days | 16 Days |
Enterprise Value | $53.87B | $8.37B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 2.38% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed from 10.91% to 2.09% over the same period. Recent news highlights expansion in data center capacity and digital partnerships, while institutional investors show mixed positioning with significant options activity.
The stock presents a growth story with data center expansion driving revenue, but faces headwinds from high debt levels (79.04% debt-to-asset ratio) and margin pressure. Analyst consensus remains bullish with a $142.75 price target representing 26% upside, though technical indicators suggest near-term caution. Key risks include interest rate sensitivity and execution challenges in digital transformation initiatives.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
